OncoMatch/Clinical Trials/NCT05491512
A Study of Reduced Radiation Therapy and Standard-of-Care Chemotherapy in People With HPV-Positive Throat Cancer
Is NCT05491512 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Cisplatin and Carboplatin for hpv.
Treatment: Cisplatin · Carboplatin · 5-fluorouracil — The purpose of this study is to find out if lower doses of radiation may help reduce the side effects of radiation therapy in combination with standard-of-care chemotherapy in people with HPV-positive throat cancer. The chemotherapy drugs used in this study include cisplatin, carboplatin, and 5-fluorouracil (5- FU), paclitaxel and abraxane- (Albumin-bound Paclitaxel).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Cancer type
Head and Neck Squamous Cell Carcinoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: head and neck radiation therapy
Subjects with prior head and neck radiation therapy
Cannot have received: systemic chemotherapy for the study cancer
Exception: prior chemotherapy for a different cancer is allowable
Prior systemic chemotherapy for the study cancer; note that prior chemotherapy for a different cancer is allowable
Lab requirements
Blood counts
WBC 2 K/mcL; ANC 1,000 cells/mm3; Platelets 100,000 cells/mm3; Hemoglobin 8.0 g/dl (transfusion or other intervention to achieve Hgb 8.0 g/dl is acceptable)
Kidney function
Serum creatinine < 1.5 mg/dl or creatinine clearance (CC) 50 ml/min determined by 24-hour collection or estimated by Cockcroft-Gault formula
Liver function
Bilirubin < 2 mg/dl; AST or ALT < 3 x the upper limit of normal (exceptions can be made with PI and/or Co-PI approval for higher Bilirubin such as Gilbert's Syndrome)
Adequate hematologic function within 30 days prior to registration, defined as follows: White Blood Count (WBC) 2 K/mcL; Absolute neutrophil count (ANC) 1,000 cells/mm3; Platelets 100,000 cells/mm3; Hemoglobin 8.0 g/dl; Note: The use of transfusion or other intervention to achieve Hgb 8.0 g/dl is acceptable. Adequate renal function within 30 days prior to registration, defined as follows: Serum creatinine < 1.5 mg/dl or creatinine clearance (CC) 50 ml/min determined by 24-hour collection or estimated by Cockcroft-Gault formula. Adequate hepatic function within 30 days prior to registration, defined as follows: Bilirubin < 2 mg/dl; AST or ALT < 3 x the upper limit of normal. Note: Exceptions can be made with PI and/or Co-Pi approval for patients to enroll on trial with a higher Bilirubin level such as Gilbert's Syndrome.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Memorial Sloan Kettering Cancer Center at Basking Ridge (Limited Protocol Activities) · Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities) · Middletown, New Jersey
- Memorial Sloan Kettering Bergen (Limited Protocol Activities) · Montvale, New Jersey
- Memorial Sloan Kettering Cancer Center at Suffolk-Commack (Limited Protocol Activities) · Commack, New York
- Memorial Sloan Kettering Westchester (Limited Protocol Activities) · Harrison, New York
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05491512 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior head and neck radiation therapy, systemic chemotherapy for the study cancer disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages